Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,002 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Etoposide Clear all
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00041015
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, topotecan hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00005613
View directory record Official record
Conditions
Lymphoma
Interventions
cyclophosphamide, etoposide, BCNU
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

NCT05192889
View directory record Official record
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation
Drug · Biological · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
4 Years to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

NCT00427791
View directory record Official record
Conditions
Leukemia
Interventions
Etoposide, Total Body Irradiation, Rituximab
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

NCT02289690
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Veliparib, Carboplatin, Etoposide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

NCT02356159
View directory record Official record
Conditions
Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
Biological · Drug · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 20, 2026, 12:22 AM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

NCT00392886
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 10 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
29
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 20, 2026, 12:22 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

NCT02700022
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Duarte, California • Chapel Hills, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 20, 2026, 12:22 AM EDT
Terminated Phase 3 Interventional

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

NCT03616470
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Uproleselan, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 20, 2026, 12:22 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

NCT00482053
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
Interventions
Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI), Rituximab, Carmustine, Etoposide, Filgrastim, Anti-thymocyte globulin (ATG), Cyclosporine, Mycophenolate mofetil (MMF), Cyclophosphamide, Acetaminophen, Diphenhydramine, Hydrocortisone, Methylprednisolone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Ruxolitinib, Dexamethasone, Etoposide
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Weeks to 22 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 2 Interventional Results available

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

NCT04952597
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 20, 2026, 12:22 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00726986
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, sorafenib tosylate
Drug
Lead sponsor
Afshin Dowlati, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
New York, New York • Cleveland, Ohio • Mayfield Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 2 Interventional

SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00002642
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, conventional surgery, low-LET cobalt-60 gamma ray therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Not applicable Interventional

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

NCT00186342
View directory record Official record
Conditions
Acute Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Myeloproliferative Disorders, Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes (MDS), Leukemia
Interventions
ablative allogeneic hematopoietic cell transplantation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
51 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Early Phase 1 Interventional

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children with Recurrent Posterior Fossa Brain Tumors

NCT02905110
View directory record Official record
Conditions
Brain Tumor Recurrent
Interventions
Methotrexate, Etoposide, Ommaya Reservoir
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 20, 2026, 12:22 AM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

NCT00004110
View directory record Official record
Conditions
Neuroblastoma
Interventions
monoclonal antibody 3F8, etoposide, isotretinoin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting Phase 2 Interventional

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

NCT05600686
View directory record Official record
Conditions
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Loncastuximab Tesirine, Prednisone, Rituximab, Vincristine
Drug · Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Recruiting Phase 2 Interventional

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

NCT04696575
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Carboplatin, Etoposide, Lamivudine
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 20, 2026, 12:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT03164057
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Drug · Combination Product · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
29 Days to 21 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Madera, California • Orange, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 12:22 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

NCT04870112
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, Etoposide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 20, 2026, 12:22 AM EDT
Not listed Phase 2 Interventional Results available

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

NCT01042522
View directory record Official record
Conditions
Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified, Ovarian Steroid Cell Tumor
Interventions
Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
219
States / cities
Anchorage, Alaska • Burbank, California • Sylmar, California + 156 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 20, 2026, 12:22 AM EDT